What is the TTK Healthcare PE ratio today?
TTK Healthcare's PE ratio is 4.6 at the 30 October 2026 close (₹905.30 a share): a market capitalisation of ₹1,279 crore divided by consolidated net profit of ₹277 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹65.7 crore) it is 19.5. These four quarters include net exceptional items of ₹244 crore (one-off gains reported separately), so the ratio on recurring profit would differ.
What is the TTK Healthcare PB ratio (price to book value)?
TTK Healthcare's price-to-book (PB) ratio is 0.95 at the 30 October 2026 close: a market capitalisation of ₹1,279 crore divided by shareholders' equity (book value) of ₹1,347 crore on 30 September 2026. That is a book value of ₹952.95 per share against a share price of ₹905.30.
What is the TTK Healthcare ROE and ROCE?
In FY26, TTK Healthcare's return on equity (ROE) was 6.0% and its return on capital employed (ROCE) was 1.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 7.9% and ROCE 2.6%.
What is the TTK Healthcare market cap?
TTK Healthcare's market capitalisation was ₹1,279 crore at the 30 October 2026 close: 1.41 crore shares at ₹905.30 each.
What is the TTK Healthcare EPS?
TTK Healthcare's basic earnings per share (EPS) were ₹46.48 in FY26, against ₹57.79 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹195.71.
What is the TTK Healthcare dividend in 2026 and its record date?
In 2026, TTK Healthcare has declared one dividend: ₹10 with record date 17 July 2026.
Is TTK Healthcare debt free?
No. TTK Healthcare had borrowings of ₹26 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.02. Its cash and current investments were ₹1,052 crore, so it held net cash of ₹1,026 crore.
What is the TTK Healthcare debt to equity ratio?
TTK Healthcare's debt-to-equity ratio was 0.02 on 30 September 2026: borrowings of ₹26 crore against total equity of ₹1,347 crore. A year earlier, on 30 September 2025, it was 0.02.
What is the TTK Healthcare promoter holding?
Promoters held 74.56% of TTK Healthcare on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the TTK Healthcare net worth?
TTK Healthcare's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,347 crore on 30 September 2026, up 24.1% from ₹1,085 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,279 crore at the 30 October 2026 close.
What is the TTK Healthcare book value per share?
TTK Healthcare's book value per share was ₹952.95 on 30 September 2026: shareholders' equity of ₹1,347 crore divided by the 1.41 crore shares in issue, up 24.1% from ₹767.91 a year earlier. The share price at the 30 October 2026 close was ₹905.30.
What are the TTK Healthcare latest quarterly results?
TTK Healthcare's latest results are for Q2 FY27 (July–September 2026), filed on 30 October 2026: consolidated net profit ₹223 crore, up 993.7% from ₹20.4 crore in Q2 FY26; revenue from operations ₹233 crore, up 14.6% year on year.
What is the TTK Healthcare dividend yield?
TTK Healthcare's dividend yield is 1.10% at the 30 October 2026 close: dividends of ₹10 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹905.30. They were ₹10 on 17 July 2026.
What is the TTK Healthcare free cash flow?
In FY26, TTK Healthcare generated ₹21.1 crore of cash from operations and spent ₹5.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹27 crore. In FY25 it was −₹16.8 crore.
When are the TTK Healthcare next results?
TTK Healthcare has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
What is the TTK Healthcare shareholding pattern?
On 30 September 2026, TTK Healthcare's shares were held by promoters 74.56%, foreign portfolio investors (FII/FPI) 1.95%, domestic institutions (DII) 0.12% and retail and other non-institutional investors 23.38%. Over the year, FII holding was up 0.05 percentage points from 1.90% and DII holding was down 1.06 percentage points from 1.18%.
How does the TTK Healthcare PE ratio compare with its peers?
At the 30 October 2026 closing prices, on FY26 net profit, TTK Healthcare's PE ratio is 19.5, the second highest of the four: DCM Shriram 16.0, Balmer Lawrie & 9.6 and Godrej Industries 24.6, a peer average of 16.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.
TTK Healthcare vs DCM Shriram: how do they compare?
In FY26, TTK Healthcare earned net profit of ₹65.7 crore on revenue of ₹857 crore, against ₹853 crore on ₹14,264 crore for DCM Shriram. TTK Healthcare's operating margin was 2.0% (DCM Shriram 7.0%) and its return on equity 6.0% (DCM Shriram 11.6%). At the 30 October 2026 close, TTK Healthcare's market capitalisation was ₹1,279 crore against ₹13,630 crore for DCM Shriram, and its PE ratio on FY26 profit 19.5 against 16.0.
What is the TTK Healthcare revenue and profit in FY26?
In FY26 (April 2025–March 2026), TTK Healthcare's consolidated net profit was ₹65.7 crore, down 19.6% from ₹81.7 crore in FY25, on revenue from operations of ₹857 crore (up 7.0%). Over three years, from FY23, net profit was down 89.7%.
How does TTK Healthcare compare with its peers?
On FY26 consolidated figures, against DCM Shriram, Balmer Lawrie & and Godrej Industries: TTK Healthcare's operating margin of 2.0% is the lowest of the four (DCM Shriram 7.0%, Balmer Lawrie & 10.1%, Godrej Industries 7.8%; peer average 8.3%); its return on equity of 6.0% is the lowest of the four (DCM Shriram 11.6%, Balmer Lawrie & 13.7%, Godrej Industries 11.6%; peer average 12.3%); its revenue growth over three years of 5.7% a year is the second highest of the four (DCM Shriram 5.7% a year, Balmer Lawrie & 5.4% a year, Godrej Industries 9.9% a year; peer average 7.0% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
